Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2-negative myeloproliferative neoplasms

Acta Haematologica

Volumn 133, Issue 2, 2015, Pages 193-198

  Wojtaszewska, Marzena ^a   Iwoła, Małgorzata ^a   Lewandowski, Krzysztof ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

CALR gene; Calreticulin; Essential thrombocythemia; Myeloproliferative neoplasms; Primary myelofibrosis

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2; CALRETICULIN; CALRETICULIN, HUMAN; JAK2 PROTEIN, HUMAN;

ADULT; AGED; ANEMIA; ARTICLE; CALRETICULIN GENE; CLINICAL FEATURE; EXON; FEMALE; GENE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLISH CITIZEN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; AMINO ACID SUBSTITUTION; BLOOD; CLINICAL TRIAL; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; POLAND; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANEMIA; CALRETICULIN; EXONS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMOGLOBINS; HUMANS; JANUS KINASE 2; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLAND; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84923145674     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000366263     Document Type: Article

References (25)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
3. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-2405.
4. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R: Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
5. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
6. Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, Mc-Mullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D: Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: A joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 2013; 27: 2032-2039.
7. Boyd EM, Bench AJ, Goday-Fernandez A, Anand S, Vaghela KJ, Beer P, Scott MA, Bareford D, Green AR, Huntly B, Erber WN: Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 2010; 149: 250-257.
8. Ugo V, Tondeur S, Menot ML, Bonnin N, Le Gac G, Tonetti C, Mansat-De Mas V, Lecucq L, Kiladjian JJ, Chomienne C, Dosquet C, Parquet N, Darnige L, Porneuf M, Escoffre-Barbe M, Giraudier S, Delabesse E, Cassinat B; French Intergroup of Myeloproliferative Disorders: Interlaboratory development and validation of an HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. PLoS One 2010; 5:e8893.
9. Ma W, Zhang X, Wang X, Zhang Z, Yeh CH, Uyeji J, Albitar M: MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders. Diagn Mol Pathol 2011; 20: 34-39.
10. Broseus J, Lippert E, Harutyunyan AS, Jeromin S, Zipperer E, Florensa L, Milosevic JD, Haferlach T, Germing U, Luno E, Schnittger S, Kralovics R, Girodon F: Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2014; 28: 1374-1376.
11. Clark RA, Li SL, Pearson DW, Leidal KG, Clark JR, Denning GM, Reddick R, Krause KH, Valente AJ: Regulation of calreticulin expression during induction of differentiation in human myeloid cells. Evidence for remodeling of the endoplasmic reticulum. J Biol Chem 2002; 277: 32369-32378.
12. Michalak M, Lynch J, Groenendyk J, Guo L, Robert Parker JM, Opas M: Calreticulin in cardiac development and pathology. Biochim Biophys Acta 2002; 1600: 32-37.
13. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL: Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2: 63ra94.
14. Mollegaard KM, Duus K, Traeholt SD, Thaysen-Andersen M, Liu Y, Palma AS, Feizi T, Hansen PR, Hojrup P, Houen G: The interactions of calreticulin with immunoglobulin G and immunoglobulin Y. Biochim Biophys Acta 2011; 1814: 889-899.
15. Mans S, Banz Y, Mueller BU, Pabst T: The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients. Blood 2012; 120: 2690-2699.
16. Cazzola M, Kralovics R: From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014; 123: 3714-3719.
17. Tefferi A, Thiele J, Vannucchi AM, Barbui T: An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014; 28: 1407-1413.
18. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative I: Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014; 123: 1552-1555.
19. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A: CALR vs. JAK2 vs. MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472-1477.
20. Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP, Hanson CA, Pardanani A: Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: Differences in phenotype and prognostic impact. Leukemia 2014; 28: 1568-1570.
21. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative I: JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544-1551.
22. Chi J, Nicolaou KA, Nicolaidou V, Koumas L, Mitsidou A, Pierides C, Manoloukos M, Barbouti K, Melanthiou F, Prokopiou C, Vassiliou GS, Costeas P: Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia 2014; 28: 1152-1154.
23. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, Finke C, Ketterling RP, Hanson CA, Pardanani A, Wolanskyj AP, Maffioli M, Casalone R, Pacilli A, Vannucchi AM, Passamonti F: Type 1 vs type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am J Hematol 2014; 89:E121-E124.
24. Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, Mannarelli C, Pacilli A, Calabresi L, Fjerza R, Pieri L, Bosi A, Manfredini R, Guglielmelli P: Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia 2014; 28: 1811-1818.
25. Tefferi A, Wassie EA, Lasho TL, Finke C, Belachew AA, Ketterling RP, Hanson CA, Pardanani A, Gangat N, Wolanskyj AP: Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014, Epub ahead of print.